Author

H. Soni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

D. BARROS-AGUIRRE· 2 shared K. Mdluli· 2 shared N. Fotouhi· 2 shared P. J. Converse· 2 shared R. Tasneen· 2 shared S. TYAGI· 2 shared S.-Y. Li· 2 shared a. garcia-perez· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

D. BARROS-AGUIRRE

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis

L. Encinas, S.-Y. Li, J. Rullas-Trincado, R. Tasneen, S. TYAGI, H. Soni, a. garcia-perez, J. Lee, R. Gonzalez del Rio, J. De Mercado, V. Sousa, I. Sosi?, S. Gobec, A. Mendoza-Losana, P. J. Converse, , E. L. Nuermberger

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.

bioRxiv · Mar 8, 2024 · PreprintPharmacology & Toxicology

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

E. Nuermberger, M. S. Martinez, O. Sanz, B. Urones, J. Esquivias, H. Soni, R. Tasneen, S. Tyagi, S.-Y. Li, P. J. Converse, H. I. Boshoff, G. T. Robertson, G. Besra, K. A. Abrahams, A. Upton, , E. N. Jimenez

Antimicrobial Agents and Chemotherapy · Jun 21, 2022Peer-reviewedPharmacology & Toxicology